CDKN2A and neoplasm: In our study, we detected methylation differences at MGMT body both in peripheral blood and in tumor samples: CDKN2A-mutated patients showed a low-level hypermethylation in leukocytes compared to other melanoma patients, while tumors showed hypomethylation compared to melanocytes.